Synthesis and antitumor activity of a new 7-azaindole derivative

Abstract

We designed and synthesized a 7-azaindole derivative(TH1082), which was characterized by ¹H NMR and ¹³C-NMR. We investigated its antitumor effects on human melanoma A375 cells, human liver cancer SMMC cells and human breast cancer MCF-7 cells in vitro via 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay and also explored the mechanism of antiproliferation of them. The results show that TH1082 significantly inhibited the proliferation of these cells to different extent. The IC₅₀ values for A375 cells, SMMC cells and MCF-7 cells were 25.38, 48.70 and 76.94 μg/mL at 24 h, respectively. To observe cell morphological changes, acridine orange/ethidium bromide(AO/EB) staining and Hoechest33342/PI staining were carried out. These results indicate that TH1082 could induced the apoptosis of A375 cells. The apoptotic rates were (9.5±2.09)%, (18.9±2.25)% and (39.5±2.02)%(5, 10 and 20 μg/mL) for A375, SMMC and MCF-7 cell lines, respectively. Further, we determined the activities of caspase-3 and caspase-9 in A375 cells treated with TH1082 at different concentrations(0, 5, 10 and 20 μg/mL) or Z-VAD-FMK(20 μmol/L), a pan-caspase inhibitor for 24 h. The results show that TH1082 activated caspase-3 and caspase-9, and the activation could be blocked by Z-VAD-FMK. Taken together, these findings indicate that TH1082 could inhibit the proliferation of A375 cells via activating caspase-3 and caspase-9.

Keywords

7-Azaindole / Antitumor / Apoptosis

References

[1] Cacchi S, Fabrizi G. Chem. Rev., 2005, 105: 2873.

[2] Humphrey G R, Kuethe J T. Chem. Rev., 2006, 106: 2875.

[3] Kochanowska-Karamyan A J, Hamann M T. Chem. Rev., 2010, 110: 4489.

[4] Jacob A P, Nicole N M, Hadi D A, Andrey P, Kim R D, Mohan N, Manickam K, Sumathy M, Judith A W. J. Inorg. Biochem., 2013, 127: 175.

[5] Florence P, Sylvain R, Benoît J, Jean-Yves M. Tetrahedron, 2007, 63: 1031.

[6] Song J J, Reeves J T, Gallou F, Tan Z T, Yee N K, Senanayake C H. Chem. Soc. Rev., 2007, 36: 1120.

[7] Zhao S B, Wang S. Chem. Soc. Rev., 2010, 39: 3142.

[8] Lebouvier N, Pagniez F, Duflos M, Pape P L, Young M N, Baut G L, Borgne M L. Bioorg. Med. Chem. Lett., 2007, 17(13): 3686.

[9] Guillard J, Decrop M, Gallay N, Espanel C, Boissier E, Herault O, Viaud-Massuard M. Bioorg. Med. Chem. Lett., 2007, 17(7): 1934.

[10] Trejo A, Arzeno H, Browner M, Chanda S, Cheng S, Comer D D, Dalrymple S A, Dunten P, Lafargue J, Lovejoy B, Freire-Moar J, Lim J, Mcintosh J, Miller J, Papp E, Reuter D, Roberts R, Sanpablo F, Saunders J, Song K, Villasenor A, Warren S D, Welch M, Weller P, Whiteley P E, Zeng L, Goldstein D M. J. Med. Chem., 2003, 46(22): 4702.

[11] Morón M, Burgos C, Alvarez-Builla J, Salgado A, Mosquera M E G, Vaquero J J. Chem. Commun., 2012, 48: 9171.

[12] José R, Venancio R, de Concepción H, Arturo E, José P, Christoph J. Dalton Trans., 2010, 39: 3290.

[13] Wang T, Wallace O B, Zhang Z X, Meanwell N A, Bender J A. Antiviral Azaindole Derivatives., 2003.

[14] Walker S R, Carter E J, Huff B C, Morris J. Chem. Rev., 2009, 109: 3080.

[15] Hong S, Lee S, Kim B, Lee H, Hong S, Hong S. Bioorg. Med. Chem. Lett., 2010, 20: 7212.

[16] Anthony J. J. Med. Chem., 1972, 15(2): 149.

[17] Hugon B, Anizon F, Bailly C, Golsteyn R M, Pierré A, Léonce S, Hickman J, Pfeiffer B, Prudhomme M. Bioorg. Med. Chem., 2007, 15(17): 5965.

[18] Dirk B M, Laird A D, Xin X H, Louie S G, Christensen J G, Li G, Schreck R, Abrams T J, Ngai T J, Lee L B, Murray L J, Carver J, Chan E, Moss K G, Haznedar J O, Sukbuntherng J, Blake R A, Sun L, Tang C, Miller T, Shirazian S, Mcmahon G, Cherrington J M. Clin. Cancer. Res., 2003, 9: 327.

[19] Motzer R J, Michaelson M D, Redman B G, Hudes G R, Wilding G, Figlin R A, Ginsberg M S, Kim S T, Baum C M, De-Primo S E, Li J Z, Bello C L, Theuer C P, George D J, Rini B I. J. Clin. Oncol., 2006, 24: 16.

[20] O’Farrell A, Abrams T J, Yuen H A, Ngai T J, Louie S G, Yee K W H, Wong L M, Hong W, Lee L B, Town A, Smolich B D, Manning W C, Murray L J, Heinrich M C, Cherrington J M. Blood, 2003, 101: 3597.

[21] Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda J Y, Chu J Y, Nematalla A, Wang X Y, Chen H, Sistla A, Luu T C, Tang F, Wei J, Tang C. J. Med. Chem., 2003, 46: 1116.

[22] Wang H Y, Ke B L, Su G F, Xu X. Chem. Res. Chinese Universities, 2012, 28(6): 1041.

[23] Chen C Y, Chen Y K, Wang J J, Hsu C C, Tsai F Y, Sung P J, Lin H C, Chang L S, Hu W P. Cell Biol. Toxicol., 2013, 29: 85.

[24] Chen T, Wong Y S. Cell. Mol. Life Sci., 2008, 65: 2763.

[25] Qu X J, Cui S X, Tian Z G, Li X, Chen M H, Xu W F, Inagaki Y, Deng Y B, Makuuchi M, Nakata M, Tang W. Anticancer Res., 2007, 27: 2427.

[26] Huang X J, Li Q, Li H G, Guo L J. Cell Mol. Neurobiol., 2009, 29: 1211.

[27] Xu H L, Yu X F, Qu S C, Zhang R, Qu X R, Chen Y P, Ma X Y, Sui D Y. Eur. J. Pharmacol., 2010, 645(1–3): 14.

[28] Qu X R, Qu S C, Yu X F, Xu H L, Chen Y P, Ma X Y, Sui D Y. Oncol. Rep., 2011, 26(6): 1441.

[29] Abrams T J, Lee L B, Murray L J, Pryer N K, Cherrington J M. Mol. Cancer Ther., 2003, 2: 471.

[30] Murray L J, Abrams T J, Long K R, Ngai T J, Olson L M, Hong W, Keast P K, Brassard J A, O’Farrell A M, Pryer N K, Cherrington J M. Clin. Exp. Metastas., 2003, 20: 757.

[31] Abrams T J, Murray L J, Pesenti E, Holway V W, Colombo T, Lee L B, Cherrington J M, Pryer N K. Mol. Cancer Ther., 2003, 2: 1011.